Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: Mark C. Hurley who wrote (560)	2/13/1998 10:57:00 PM
From: John McCarthy	Read Replies (3) \| Respond to of 849

Mark - Welcome to the thread! Well, I hate to start off by giving you a downer but I absolutely agree with your post. The bladder test is - great science. Period. I for one, don't have a clue what the real problem is. I do know (5 yrs+ exp.) a fair amount about the marketing of consumer products, and therefore, the importance of being in the right distribution channels, at least, with respect to certain types of consumer goods. I suspect - but am not certain - that this is part of the problem with the Bladder test. And I also suspect, given the length of time it took them to realize that they needed new marketing/management talent, that current top management is really ill-prepared to run a business; i.e. their deadbeats. I do not say this lightly or just to run at the mouth. I really mean it. Lastly, the reason(s) I am hanging my hat on the colon thing is twofold: (a) There is no real (as best I understand it) current competitor to this colon test. So, hopefully doctors will embrace it. (b) By all means, if we can't get in the front door with the bladder product, lets have it 'tag a long' with the colon product - BUT ONLY AFTER - the colon product is established. Regards John

To: Mark C. Hurley who wrote (560)	2/16/1998 9:48:00 AM
From: Wesley0428	Read Replies (1) \| Respond to of 849

<<<I am new to this site, but not new to Matritech. I read through these folders and there was pretty good information in here.>>> Welcome. Maybe you should read these folders more closely. <<< I agree with John that the colorectal cancer product that is in Phase I of FDA clinical trials (4 months now) is the big money maker for this stock.>>> It's awaiting FDA 510k approval, which would be considered the final approval stage in this case. <<<But noone should cross off the NMP22 test kit. It is still the best prostate cancer screening test around>>> NMP22 is a bladder cancer test <<<I read posts from a while ago with concern over Bayer backing out on Matritech's colorectal test.>>> Bayer's deal is to automate a cervical cancer test <<<Don't forget that Bayer has made a large contribution in money to Matritech.>>> Bayer's financial contribution to Matritech to date is minimal